Synteract Achieves Study Build Accreditation in Medidata Solutions Channel Partner Program

Full-service CRO Continues to Increase Global Presence through Medidata Rave Accreditation

NEW YORK--(BUSINESS WIRE)-- Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced that Synteract Inc. has attained the study build accreditation in Medidata’s channel partner program. With this accreditation, Synteract can now provide the full suite of Medidata Rave® electronic data capture (EDC) and clinical data management (CDM) services to sponsors.

A channel partner since June 2010, Synteract is a full-service contract research organization (CRO) with an increasing global presence and extensive experience working with emerging biotech, pharmaceutical and medical device sponsors. Impressed by Medidata Rave’s flexibility and scalability, Synteract viewed this partnership milestone as important to its continued efforts to expand internationally while providing sponsors with the highest level of Rave support.

“Attaining the Medidata Rave study build accreditation demonstrates our dedication to bringing optimal efficiencies to our customers for global trials of all sizes,” said Stewart Bieler, chief operating officer, Synteract. “The implementation success we’ve experienced due to Rave’s flexibility and monitoring offerings made it clear that expanding our partnership with Medidata would help us move toward our next stage of growth.”

The new accreditation enables Synteract to serve as a single source for sponsors to acquire all Rave-related services, including end user training, study build, reporting, outputs, integrations and migrations. With more than 16 years of experience providing responsive, flexible service, Synteract can manage all aspects of trials, including EDC activities.

“Since becoming a Medidata partner last year, Synteract has quickly realized the benefits of the program, expanding its reach to include the wide range of sponsors who are relying more frequently on Medidata Rave for global trials,” said Graham Bunn, vice president of partnerships and alliances, Medidata Solutions. “As the CRO market continues to evolve, Synteract recognizes partnership with Medidata as necessary to its ability to maintain steady growth and competitiveness.”

Medidata first announced its channel partner program in April 2005 to enable select CROs and other service providers to offer Medidata Rave implementation services. Since then, the program has grown to include more than 30 partners, ranging from smaller clinical consultancies to large, global CROs.

About Synteract

Synteract is a privately-held, full-service contract research organization, serving clinical trial needs of biotechnology, medical device and pharmaceutical companies. Synteract provides high-quality, customized service, working closely with drug and device sponsors. Headquartered in California, with offices in North Carolina and Czech Republic, Synteract offers clinical expertise in multiple therapeutic areas, including a strong emphasis in oncology, central nervous system (CNS), cardiovascular, respiratory and ophthalmology.

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of SaaS clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced solutions lower the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design (Medidata Designer®), trial planning and Medidata Grants Manager®, Medidata CRO Contractor®),, site negotiation (Medidata Grants Manager Contracting™), clinical portal (iMedidata™), randomization and trial supply management (Medidata Balance™), clinical data capture and management (Medidata Rave®), monitoring (Medidata Rave Monitor, Medidata Rave Targeted SDV), safety events capture (Medidata Rave Safety Gateway), to business analytics (Medidata Insights™). Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.


For Medidata:
Lois Paul & Partners
Susan McCarron, 781-782-5767
[email protected]
For Synteract:
Clearpoint Agency, Inc.
Beth Walsh, 760-230-2424
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Technology  Data Management  Hardware  Software  Health  Biotechnology  Clinical Trials  Medical Devices  Pharmaceutical



Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.